145 | SONROTOCLAX (BGB‐11417), A NOVEL BCL2 INHIBITOR, PLUS ZANUBRUTINIB (ZANU) DEMONSTRATES DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY CLL/SLL: UPDATED PHASE 1 RESULTS | Publicación